The Impact of COVID-19 on Pulmonary Procedures
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorM.D. Anderson Cancer Center
About this trial
This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.
Eligibility criteria
Qualifiers
Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)
These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership
Disqualifiers
None
Trial design
Treatments tested in this trial
- Survey Administration
Treatment groups
250 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov